On February 19, 2019, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the 2017 edition of Meds Entry Watch. According to the notice, this publication provides information on new medicines entering Canadian and international markets. The 2017 edition examines the availability, sales, uptake, pricing, and treatment costs of new medicines approved by the US Food and Drug Administration, the European Medicines Agency, and/or Health Canada in 2016 and 2017, as well as trends, going back to 2009. This edition also includes an analysis of biosimilars approved between 2006 and 2017.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
